29 Jul 2022 10:00
Issued: 29 July 2022, London UK
Â
GSK Board change
Â
Â
Â
Â
GSK plc (LSE/NYSE: GSK) has today announced that Dr Laurie Glimcher has advised the Company of her intention to retire from the Board on 13 October 2022 after over 5 years as a Non-Executive Director and designated Scientific and Medical Expert.
Â
GSK expects to announce further Non-Executive Director appointments in due course.
Â
Â
Victoria Whyte
Company Secretary
29 July 2022
Â
Â
Notes
Â
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company
Â
GSK enquiries | |||
Media: | Tim Foley | +44 (0) 20 8047 5502 | (London) |
Kathleen Quinn | +1 202 603 5003 | (Washington DC) | |
 | |||
Investor Relations: | Nick Stone | +44 (0) 7717 618834 | (London) |
James Dodwell | +44 (0) 20 8047 2406 | (London) | |
Mick Readey | +44 (0) 7990 339653 | (London) | |
Josh Williams | +44 (0) 7385 415719 | (London) | |
Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |
Â
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and any impacts of the COVID-19 pandemic.
Â
Registered in England & Wales:
No. 3888792
Â
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
Glaxosmithkline (GSK)